

# Romano Danesi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4509314/publications.pdf>

Version: 2024-02-01

422  
papers

14,385  
citations

22548

61  
h-index

43601

95  
g-index

431  
all docs

431  
docs citations

431  
times ranked

19809  
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity. <i>Cancer Research</i> , 2010, 70, 4528-4538.	0.4	409
2	Molecular basis of resistance to azole antifungals. <i>Trends in Molecular Medicine</i> , 2002, 8, 76-81.	3.5	381
3	Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with Gemcitabine. <i>Cancer Research</i> , 2006, 66, 3928-3935.	0.4	307
4	Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. <i>JAMA Oncology</i> , 2019, 5, 343.	3.4	280
5	The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>European Urology</i> , 2017, 71, 680-687.	0.9	213
6	Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. <i>Drug Resistance Updates</i> , 2003, 6, 71-84.	6.5	207
7	Correlation of <i>CDA</i> , <i>ERCC1</i> , and <i>XPD</i> Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2008, 14, 1797-1803.	3.2	193
8	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. <i>British Journal of Cancer</i> , 2018, 118, 820-824.	2.9	190
9	Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non-Small-Cell Lung Cancer Cells. <i>Molecular Pharmacology</i> , 2005, 68, 110-118.	1.0	176
10	Effect of <i>SLCO1B3</i> Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3312-3318.	3.2	175
11	Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs. <i>Clinical Pharmacokinetics</i> , 2002, 41, 431-444.	1.6	168
12	Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2019, 77, 20-28.	3.4	159
13	The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2496-2508.	1.9	157
14	Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 103-122.	2.0	154
15	Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. <i>Molecular Cancer</i> , 2011, 10, 40.	7.9	150
16	Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells. <i>Molecular Pharmacology</i> , 2008, 73, 1290-1300.	1.0	149
17	The pharmacological bases of the antiangiogenic activity of paclitaxel. <i>Angiogenesis</i> , 2013, 16, 481-492.	3.7	149
18	Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 4006-4014.	0.8	148

#	ARTICLE	IF	CITATIONS
19	EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 753-761.	2.7	148
20	Clinical pharmacology of intravitreal anti-VEGF drugs. <i>Eye</i> , 2018, 32, 1010-1020.	1.1	143
21	<i>DPYD</i> VS14+1G&gt;A and 2846A&gt;T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. <i>Pharmacogenomics</i> , 2013, 14, 1255-1272.	0.6	126
22	Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. <i>Drug Resistance Updates</i> , 2011, 14, 280-296.	6.5	113
23	Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN-38. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 854-860.	1.0	107
24	The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. <i>Drugs</i> , 2017, 77, 671-677.	4.9	106
25	Periorbital necrotising fasciitis. <i>British Journal of Ophthalmology</i> , 2010, 94, 1577-1585.	2.1	97
26	Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. <i>Annals of Oncology</i> , 2001, 12, 1301-1306.	0.6	94
27	Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 95.	3.5	94
28	Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines. <i>Clinical Cancer Research</i> , 2004, 10, 2936-2943.	3.2	90
29	Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 1997, 15, 2510-2517.	0.8	89
30	Cardiotoxicity of Epirubicin/Paclitaxel-Containing Regimens: Role of Cardiac Risk Factors. <i>Journal of Clinical Oncology</i> , 1999, 17, 3596-3602.	0.8	89
31	CYP2D6 polymorphisms and the impact on tamoxifen therapy. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 2224-2231.	1.6	89
32	Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. <i>Lung Cancer</i> , 2018, 115, 21-27.	0.9	87
33	Suramin in Adrenal Cancer: Modulation of Steroid Hormone Production, Cytotoxicity <i>in Vitro</i> , and Clinical Antitumor Effect*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 71, 497-504.	1.8	86
34	EPMA position paper in cancer: current overview and future perspectives. <i>EPMA Journal</i> , 2015, 6, 9.	3.3	86
35	Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. <i>British Journal of Cancer</i> , 2008, 98, 1619-1629.	2.9	85
36	Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 4954-4962.	3.2	85

#	ARTICLE	IF	CITATIONS
37	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2011, 104, 1262-1269.	2.9	85
38	Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1735-1746.	1.9	84
39	Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1387-1395.	1.9	83
40	Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*. <i>Breast Cancer Research and Treatment</i> , 2001, 68, 171-179.	1.1	82
41	Contribution of <i>KRAS</i> mutations and c.2369C > T (p.T790M) <i>EGFR</i> to acquired resistance to EGFR-TKIs in <i>EGFR</i> mutant NSCLC: a study on circulating tumor DNA. <i>Oncotarget</i> , 2017, 8, 13611-13619.	0.8	81
42	Hematologic toxicity of immunosuppressive treatment. <i>Transplantation Proceedings</i> , 2004, 36, 703-704.	0.3	80
43	Association of the <i>CYP1B1*3</i> allele with survival in patients with prostate cancer receiving docetaxel. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 19-26.	1.9	79
44	Pharmacological Issues of Linezolid. <i>Clinical Pharmacokinetics</i> , 2010, 49, 439-447.	1.6	75
45	Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS) Tj ETQq1 1 0.784314 rgBT / Overlock	3.2	75
46	Effect of Suramin on Human Prostate Cancer Cells in Vitro. <i>Journal of Urology</i> , 1991, 145, 393-398.	0.2	74
47	Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. <i>British Journal of Cancer</i> , 1993, 68, 932-938.	2.9	74
48	Polycomb genes and cancer: Time for clinical application?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 184-193.	2.0	74
49	BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. <i>International Journal of Cancer</i> , 2011, 128, 1946-1954.	2.3	73
50	ALK-1â€“Negative Anaplastic Large Cell Lymphoma Associated With Breast Implants: A New Clinical Entity. <i>Clinical Breast Cancer</i> , 2011, 11, 283-296.	1.1	72
51	The emerging role of histone lysine demethylases in prostate cancer. <i>Molecular Cancer</i> , 2012, 11, 52.	7.9	72
52	Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E288-E296.	1.8	71
53	Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 57-62.	1.1	71
54	Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. <i>British Journal of Cancer</i> , 2005, 93, 319-330.	2.9	69

#	ARTICLE	IF	CITATIONS
55	The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOMâ€“SIAPEC-IAPâ€“SIBioCâ€“SICâ€“SIF Italian Scientific Societies. ESMO Open, 2021, 6, 100164.	2.0	69
56	An Improved HPLC Method for Therapeutic Drug Monitoring of Daunorubicin, Idarubicin, Doxorubicin, Epirubicin, and Their 13-Dihydro Metabolites in Human Plasma. Therapeutic Drug Monitoring, 1999, 21, 367.	1.0	68
57	Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clinical Cancer Research, 2000, 6, 3032-7.	3.2	68
58	Association of Polymorphisms in <i>AKT1</i> and <i>EGFR</i> with Clinical Outcome and Toxicity in Nonâ€“Small Cell Lung Cancer Patients Treated with Gefitinib. Molecular Cancer Therapeutics, 2010, 9, 581-593.	1.9	67
59	Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Scientific Reports, 2017, 7, 7931.	1.6	66
60	Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer. Pharmacological Reviews, 2003, 55, 57-103.	7.1	65
61	Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment. Stem Cells Translational Medicine, 2018, 7, 305-314.	1.6	65
62	Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open, 2022, 7, 100404.	2.0	65
63	Cancer stem cell epigenetics and chemoresistance. Epigenomics, 2009, 1, 63-79.	1.0	64
64	Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. British Journal of Cancer, 2005, 93, 35-40.	2.9	63
65	A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clinical Pharmacology and Therapeutics, 2006, 80, 384-395.	2.3	63
66	A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. British Journal of Cancer, 2008, 98, 1312-1319.	2.9	63
67	Impact of <i>ABCG2</i> polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics, 2011, 12, 159-170.	0.6	63
68	Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica, 2011, 96, 937-942.	1.7	62
69	Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. International Journal of Molecular Sciences, 2019, 20, 3951.	1.8	62
70	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis, 2012, 15, 275-286.	3.7	61
71	A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU International, 2008, 102, 617-621.	1.3	60
72	Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples. Nucleosides, Nucleotides and Nucleic Acids, 2008, 27, 720-725.	0.4	60

#	ARTICLE	IF	CITATIONS
73	Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper. <i>Hematological Oncology</i> , 2019, 37, 3-14.	0.8	59
74	Antimicrobial peptides: therapeutic potential for the treatment of <i>Candida</i> infections. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 309-318.	1.9	58
75	Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 839-848.	0.8	57
76	Expression of nucleoside transporters, deoxycytidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 679-686.	1.1	56
77	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. <i>Cancer Treatment Reviews</i> , 2017, 55, 71-82.	3.4	56
78	Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 306-315.	1.9	56
79	Suramin, a novel antitumor compound. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1990, 37, 893-898.	1.2	55
80	Macrolide antibiotics as antiinflammatory agents: Roxithromycin in an unexpected role. <i>Agents and Actions</i> , 1993, 38, 85-90.	0.7	55
81	Periodontal Tissue Disposition of Azithromycin. <i>Journal of Periodontology</i> , 1997, 68, 1206-1209.	1.7	55
82	Pharmacogenetic determinants of anti-cancer drug activity and toxicity. <i>Trends in Pharmacological Sciences</i> , 2001, 22, 420-426.	4.0	54
83	<i>ABC B1</i> polymorphisms are associated with clozapine plasma levels in psychotic patients. <i>Pharmacogenomics</i> , 2009, 10, 1267-1276.	0.6	53
84	Histone lysine demethylases in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 97-103.	2.0	53
85	Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 7099-7107.	3.2	52
86	Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. <i>Pharmacogenomics</i> , 2007, 8, 49-66.	0.6	52
87	5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 2749-2755.	3.2	52
88	Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 584-97.	1.3	52
89	Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients. <i>Journal of Clinical Oncology</i> , 2001, 19, 3456-3462.	0.8	51
90	Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 205-212.	1.1	49

#	ARTICLE	IF	CITATIONS
91	Design, Synthesis, and Characterization of the Antitumor Activity of Novel Ceramide Analogues. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 3994-4000.	2.9	49
92	CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E528-E536.	1.8	49
93	Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. <i>Clinical Lung Cancer</i> , 2017, 18, 692-697.	1.1	49
94	Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. <i>Annals of Oncology</i> , 2002, 13, 919-927.	0.6	48
95	Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 939-945.	1.3	48
96	Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa563.	0.4	48
97	Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. <i>BMC Cancer</i> , 2010, 10, 511.	1.1	47
98	Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity. <i>Current Drug Metabolism</i> , 2011, 12, 932-943.	0.7	47
99	Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 250-255.	1.1	47
100	Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. <i>Pharmacological Research</i> , 2016, 103, 149-157.	3.1	47
101	Radiomics and liquid biopsy in oncology: the holons of systems medicine. <i>Insights Into Imaging</i> , 2018, 9, 915-924.	1.6	47
102	A pilot study of suramin in the treatment of metastatic renal cell carcinoma. <i>Cancer</i> , 1991, 67, 1509-1513.	2.0	46
103	CLM3, a Multitarget Tyrosine Kinase Inhibitor With Antiangiogenic Properties, Is Active Against Primary Anaplastic Thyroid Cancer In Vitro and In Vivo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E572-E581.	1.8	46
104	ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1419-1432.	1.5	46
105	Teratogenesis and immunosuppressive treatment. <i>Transplantation Proceedings</i> , 2004, 36, 705-707.	0.3	45
106	The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. <i>Pharmacogenomics Journal</i> , 2014, 14, 328-335.	0.9	45
107	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Translational Lung Cancer Research</i> , 2017, 6, 373-386.	1.3	45
108	Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2011, 6, 395-396.	0.5	44

#	ARTICLE	IF	CITATIONS
109	Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. <i>Cancer Treatment Reviews</i> , 2020, 84, 101966.	3.4	44
110	Pharmacokinetic Optimisation of Treatment Schedules for Anthracyclines and Paclitaxel in Patients with Cancer. <i>Clinical Pharmacokinetics</i> , 1999, 37, 195-211.	1.6	43
111	Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. <i>European Journal of Pharmacology</i> , 2004, 498, 9-18.	1.7	43
112	In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. <i>British Journal of Cancer</i> , 2006, 95, 289-297.	2.9	43
113	Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 809-824.	1.9	43
114	Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. <i>Molecular Pharmacology</i> , 1995, 47, 1106-11.	1.0	43
115	Specific Labeling of Isoprenylated Proteins: Application to Study Inhibitors of the Post-translational Farnesylation and Geranylgeranylation. <i>Biochemical and Biophysical Research Communications</i> , 1995, 206, 637-643.	1.0	42
116	Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 508-518.	1.1	42
117	From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. <i>Lung Cancer</i> , 2019, 131, 78-85.	0.9	42
118	Implications of KRAS mutations in acquired resistance to treatment in NSCLC. <i>Oncotarget</i> , 2018, 9, 6630-6643.	0.8	42
119	Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. <i>Pharmacogenomics</i> , 2009, 10, 69-80.	0.6	41
120	VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. <i>British Journal of Cancer</i> , 2013, 109, 957-964.	2.9	41
121	In-vitro evidence of autocrine secretion of vascular endothelial growth factor by endothelial cells from human placental blood vessels. <i>Molecular Human Reproduction</i> , 2001, 7, 771-777.	1.3	40
122	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2012, 23, 1207-1213.	0.6	40
123	Clinical Pharmacokinetics of Antibacterials in Cerebrospinal Fluid. <i>Clinical Pharmacokinetics</i> , 2013, 52, 511-542.	1.6	40
124	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103436.	2.0	40
125	The Heparan Sulfate Suleparioide Inhibits Rat Corneal Angiogenesis and in vitro Neovascularization. <i>Experimental Eye Research</i> , 1998, 67, 133-142.	1.2	39
126	Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1964-1973.	1.9	39



#	ARTICLE	IF	CITATIONS
127	The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response. <i>British Journal of Cancer</i> , 2018, 119, 1252-1258.	2.9	39
128	Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta -analysis of published trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 12-20.	2.0	37
129	Metronomic Ceramide Analogs Inhibit Angiogenesis in Pancreatic Cancer through Up-regulation of Caveolin-1 and Thrombospondin-1 and Down-regulation of Cyclin D1. <i>Neoplasia</i> , 2012, 14, 833-IN11.	2.3	36
130	Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. <i>European Journal of Pharmacology</i> , 2009, 619, 8-14.	1.7	35
131	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 556-563.	0.9	35
132	Geranylgeranyl Diphosphate-Based Inhibitors of Post-Translational Geranylgeranylation of Cellular Proteins. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 1352-1356.	2.9	34
133	Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. <i>Laboratory Investigation</i> , 2008, 88, 773-784.	1.7	34
134	Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumourcells. <i>British Journal of Cancer</i> , 2000, 82, 905-912.	2.9	33
135	First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study. <i>Investigational New Drugs</i> , 2012, 30, 1725-1730.	1.2	33
136	Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1465-E1473.	1.8	33
137	Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. <i>Cancer</i> , 2014, 120, 3923-3931.	2.0	33
138	Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2015, 16, 22811-22829.	1.8	33
139	The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review. <i>Respiratory Research</i> , 2018, 19, 154.	1.4	33
140	A Rapid High-Performance Liquid Chromatography Method to Measure Linezolid and Daptomycin Concentrations in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 200-205.	1.0	32
141	Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?. <i>Pharmacological Research</i> , 2016, 107, 398-406.	3.1	32
142	Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells. <i>Stem Cells</i> , 2018, 36, 633-640.	1.4	32
143	Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castration-resistant prostate cancer. <i>BJU International</i> , 2019, 124, 693-700.	1.3	32
144	Understanding EGFR heterogeneity in lung cancer. <i>ESMO Open</i> , 2020, 5, e000919.	2.0	32

#	ARTICLE	IF	CITATIONS
145	Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 524-531.	2.0	32
146	Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non-“Small-Cell Lung Cancer Is Rare. <i>Journal of Clinical Oncology</i> , 2004, 22, 4966-4970.	0.8	31
147	Irinotecan Synergistically Enhances the Antiproliferative and Proapoptotic Effects of Axitinib In Vitro and Improves Its Anticancer Activity In Vivo. <i>Neoplasia</i> , 2011, 13, 217-223.	2.3	31
148	Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. <i>Journal of Theoretical Biology</i> , 2016, 389, 263-273.	0.8	31
149	Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins. <i>International Journal of Molecular Sciences</i> , 2017, 18, 104.	1.8	31
150	Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. <i>Cancer Treatment Reviews</i> , 2019, 74, 21-28.	3.4	31
151	Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. <i>British Journal of Cancer</i> , 2005, 92, 681-689.	2.9	30
152	Association of a CYP17 Polymorphism with Overall Survival in Caucasian Patients with Androgen-Independent Prostate Cancer. <i>Urology</i> , 2007, 70, 217-220.	0.5	30
153	Pharmacogenomics in non-small-cell lung cancer chemotherapy. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 408-417.	6.6	30
154	An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw. <i>Biomarkers in Medicine</i> , 2012, 6, 201-209.	0.6	30
155	Real-time qPCR and Droplet Digital PCR: two techniques for detection of the JAK2 <sup>V617F</sup> mutation in Philadelphia-negative chronic myeloproliferative neoplasms. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 766-773.	0.7	30
156	KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. <i>European Journal of Cancer</i> , 2020, 137, 57-68.	1.3	30
157	Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 809-816.	0.7	29
158	VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. <i>Pharmacogenomics</i> , 2013, 14, 623-630.	0.6	29
159	Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2016, 34, 760-770.	1.2	29
160	Cyclins of phases G1, S and G2/M are overexpressed in aneuploid mammary carcinomas. <i>Cytometry</i> , 2000, 42, 254-260.	1.8	28
161	Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. <i>Pharmacological Research</i> , 2007, 55, 343-349.	3.1	28
162	In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. <i>European Journal of Clinical Investigation</i> , 2007, 37, 700-708.	1.7	28

#	ARTICLE	IF	CITATIONS
163	Estrogen Receptor $\pm$ and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E368-E372.	1.8	28
164	Pharmacogenetics of anti-estrogen treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 442-450.	3.4	28
165	Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 483-494.	1.1	28
166	Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. <i>ESMO Open</i> , 2021, 6, 100231.	2.0	28
167	IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in <i>RAS</i> mutant metastatic colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 16887-16898.	0.8	28
168	METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 986-988.	1.3	27
169	Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. <i>Pharmacogenomics</i> , 2012, 13, 1037-1053.	0.6	27
170	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2014, 9, 205-214.	1.7	27
171	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1667-1678.	2.0	27
172	Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2000, 11, 821-827.	0.6	26
173	Suppression of Fas Expression and Down-Regulation of Fas Ligand in Highly Aggressive Human Thyroid Carcinoma. <i>Laboratory Investigation</i> , 2000, 80, 1413-1419.	1.7	26
174	Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. <i>Biochemical Pharmacology</i> , 2011, 81, 1309-1316.	2.0	26
175	Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 165-178.	2.0	26
176	Protein kinase inhibitors for the treatment of advanced and progressive radioresistant thyroid tumors: From the clinical trials to the real life. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 319-334.	2.2	26
177	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. <i>Kidney International</i> , 2020, 98, 1108-1119.	2.6	26
178	Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy. <i>Cancers</i> , 2021, 13, 771.	1.7	26
179	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103567.	2.0	26
180	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	2.0	26

#	ARTICLE	IF	CITATIONS
181	Case Report of a Successful Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Bacteremia and MRSA/Vancomycin-Resistant <i>Enterococcus faecium</i> Cholecystitis by Daptomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2458-2459.	1.4	25
182	Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications. <i>Cancer Treatment Reviews</i> , 2013, 39, 784-792.	3.4	25
183	<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , 2018, 9, 7859-7866.	0.8	25
184	Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 593831.	1.3	25
185	Improved Analysis of 5-Fluorouracil and 5,6-Dihydro-5-Fluorouracil by HPLC With Diode Array Detection for Determination of Cellular Dihydropyrimidine Dehydrogenase Activity and Pharmacokinetic Profiling. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 362-368.	1.0	24
186	Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 21-44.	2.0	24
187	Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1137-1141.	1.3	24
188	Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. <i>Clinical Lung Cancer</i> , 2020, 21, 232-237.	1.1	24
189	Relationship Between Plasma Concentrations of 5-Fluorouracil and 5-Fluoro-5,6-Dihydrouracil and Toxicity of 5-Fluorouracil Infusions in Cancer Patients. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 588-593.	1.0	23
190	Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 627-637.	2.3	23
191	A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed. <i>Clinical Cancer Research</i> , 2004, 10, 1657-1663.	3.2	23
192	Pharmacogenomics and cancer stem cells: a changing landscape?. <i>Trends in Pharmacological Sciences</i> , 2011, 32, 487-494.	4.0	23
193	The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. <i>Pharmacogenomics</i> , 2019, 20, 49-68.	0.6	23
194	PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. <i>Pharmacological Research</i> , 2021, 163, 105241.	3.1	23
195	Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. <i>Trends in Molecular Medicine</i> , 2000, 6, 475-482.	2.6	22
196	Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells. <i>British Journal of Cancer</i> , 2001, 84, 1535-1543.	2.9	22
197	Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?. <i>EPMA Journal</i> , 2010, 1, 495-502.	3.3	22
198	Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. <i>Pharmacogenomics Journal</i> , 2010, 10, 180-190.	0.9	22

#	ARTICLE	IF	CITATIONS
199	Linezolid in the central nervous system: Comparison between cerebrospinal fluid and plasma pharmacokinetics. <i>Scandinavian Journal of Infectious Diseases</i> , 2011, 43, 721-727.	1.5	22
200	Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. <i>Lung Cancer</i> , 2011, 74, 197-205.	0.9	22
201	Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. <i>Epigenomics</i> , 2015, 7, 757-765.	1.0	22
202	erbB in NSCLC as a molecular target: current evidences and future directions. <i>ESMO Open</i> , 2020, 5, e000724.	2.0	22
203	Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients. <i>Current Clinical Pharmacology</i> , 2006, 1, 311-323.	0.2	22
204	Pharmacogenetics of neoplastic diseases: new trends. <i>Pharmacological Research</i> , 2004, 49, 331-342.	3.1	21
205	Synergistic Cytotoxicity and Molecular Interaction on Drug Targets of Sorafenib and Gemcitabine in Human Pancreas Cancer Cells. <i>Chemotherapy</i> , 2010, 56, 303-312.	0.8	21
206	Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing. <i>Journal of Clinical Oncology</i> , 2010, 28, e221-e222.	0.8	21
207	Metronomic Chemotherapy for Metastatic Prostate Cancer. <i>Drugs and Aging</i> , 2010, 27, 689-696.	1.3	21
208	A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. <i>Oncology Letters</i> , 2013, 6, 1487-1491.	0.8	21
209	CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. <i>Molecular and Cellular Endocrinology</i> , 2014, 393, 56-64.	1.6	21
210	Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours?. <i>Pharmacological Research</i> , 2020, 156, 104786.	3.1	21
211	Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients. <i>Oncotarget</i> , 2015, 6, 28743-28754.	0.8	21
212	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	3.4	21
213	Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. <i>International Journal of Cancer</i> , 1995, 63, 124-129.	2.3	20
214	Linezolid Cerebrospinal Fluid Concentration in Central Nervous System Infection. <i>Journal of Chemotherapy</i> , 2007, 19, 90-93.	0.7	20
215	EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. <i>Pharmacogenomics</i> , 2018, 19, 727-740.	0.6	20
216	Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Endocrinologia (SIE)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , 2021, 6, 100155.	2.0	20

#	ARTICLE	IF	CITATIONS
217	What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA. <i>Clinica Chimica Acta</i> , 2021, 520, 168-171.	0.5	20
218	Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. <i>ESMO Open</i> , 2021, 6, 100040.	2.0	19
219	Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 547-558.	1.1	18
220	Determinants of bone specific metastasis in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 59-66.	2.0	18
221	Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 745-754.	1.1	18
222	Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 593-595.	0.8	17
223	In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma. <i>European Journal of Pharmacology</i> , 2006, 549, 27-34.	1.7	17
224	Overexpression and Functional Relevance of Somatostatin Receptor-1, -2, and -5 in Endometrium and Endometriotic Lesions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5315-5319.	1.8	17
225	Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 453-468.	1.5	17
226	Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro. <i>Surgery</i> , 2014, 156, 1167-1176.	1.0	17
227	Refining sorafenib therapy: lessons from clinical practice. <i>Future Oncology</i> , 2015, 11, 449-465.	1.1	17
228	Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence. <i>Journal of Medical Virology</i> , 2022, 94, 491-498.	2.5	17
229	Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature. <i>Endocrine Practice</i> , 2013, 19, 1043-1049.	1.1	16
230	Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. <i>Pharmacogenomics</i> , 2014, 15, 1985-1999.	0.6	16
231	Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1799-1817.	1.4	16
232	The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report. <i>BMC Cancer</i> , 2019, 19, 410.	1.1	16
233	Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188463.	3.3	16
234	Population Pharmacokinetic Analysis of 5-FU and 5-FDHU in Colorectal Cancer Patients: Search for Biomarkers Associated with Gastro-Intestinal Toxicity. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 1713-1719.	1.0	15

#	ARTICLE	IF	CITATIONS
235	Genetic variation: effect on prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 446-456.	3.3	15
236	Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors. <i>Cancer Treatment Reviews</i> , 2017, 57, 28-35.	3.4	15
237	Individualized dosing with axitinib: rationale and practical guidance. <i>Future Oncology</i> , 2018, 14, 861-875.	1.1	15
238	Variable Correlation Between 6-Mercaptopurine Metabolites in Erythrocytes and Hematologic Toxicity: Implications for Drug Monitoring in Children With Acute Lymphoblastic Leukemia. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 375-382.	1.0	15
239	Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 2435.	1.7	15
240	Ceramide analogues in apoptosis: a new strategy for anticancer drug development. <i>Il Farmaco</i> , 2003, 58, 205-211.	0.9	14
241	Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach. <i>Journal of Thoracic Oncology</i> , 2011, 6, 768-773.	0.5	14
242	Faithful Markers of Circulating Cancer Stem Cells: Is CD133 Sufficient for Validation in Clinics?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3487-3488.	0.8	14
243	Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2012, 41, e24-e30.	0.8	14
244	A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 602-609.	1.0	14
245	The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88021-88033.	0.8	14
246	Roxithromycin Penetration into Gingiva and Alveolar Bone of Odontoiatric Patients. <i>Chemotherapy</i> , 1990, 36, 332-336.	0.8	13
247	Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 585-593.	1.1	13
248	Study of Apoptosis Induction and Deoxycytidine Kinase/Cytidine Deaminase Modulation in the Synergistic Interaction of a Novel Ceramide Analog and Gemcitabine in Pancreatic Cancer Cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2010, 29, 419-426.	0.4	13
249	Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S111-S117.	1.5	13
250	The rs2071559 AA-VEGFR-2 Genotype Frequency Is Significantly Lower in Neovascular Age-Related Macular Degeneration Patients. <i>Scientific World Journal</i> , The, 2012, 2012, 1-6.	0.8	13
251	Different Recommendations for Daptomycin Dosing Over Time in Patients With Severe Infections. <i>Clinical Infectious Diseases</i> , 2014, 58, 1788-1789.	2.9	13
252	Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Endocrinologia (SIE)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , 2021, 6, 100153.	2.0	13

#	ARTICLE	IF	CITATIONS
253	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. <i>Pharmacological Research</i> , 2021, 169, 105643.	3.1	13
254	Cyclins of phases G1, S and G2/M are overexpressed in aneuploid mammary carcinomas. <i>Cytometry</i> , 2000, 42, 254-260.	1.8	13
255	Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12007-12007.	0.8	13
256	Patients with NSCLC may display a low ratio of p.T790M <i>&lt;i&gt;vs.&lt;/i&gt;</i> activating EGFR mutations in plasma at disease progression: implications for personalised treatment. <i>Oncotarget</i> , 2017, 8, 86056-86065.	0.8	13
257	Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas. <i>British Journal of Cancer</i> , 2001, 85, 1425-1431.	2.9	12
258	Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients. <i>Current Cancer Drug Targets</i> , 2010, 10, 37-45.	0.8	12
259	Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. <i>EPMA Journal</i> , 2015, 6, 17.	3.3	12
260	Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant. <i>Pharmacogenomics</i> , 2016, 17, 5-9.	0.6	12
261	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 767-773.	1.1	12
262	Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?. <i>Annals of Oncology</i> , 2017, 28, 183.	0.6	12
263	Precision Medicine in Lymphoma by Innovative Instrumental Platforms. <i>Frontiers in Oncology</i> , 2019, 9, 1417.	1.3	12
264	A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 182, 113132.	1.4	12
265	Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. <i>Communications Biology</i> , 2021, 4, 370.	2.0	12
266	Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. <i>Pharmacological Research</i> , 2021, 167, 105537.	3.1	12
267	Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103572.	2.0	12
268	Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 133-140.	1.1	11
269	Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. <i>Pharmacogenomics Journal</i> , 2021, 21, 233-242.	0.9	11
270	Pharmacokinetic Optimisation of the Treatment of Cancer with High Dose Zidovudine. <i>Clinical Pharmacokinetics</i> , 1998, 34, 173-180.	1.6	10



#	ARTICLE	IF	CITATIONS
271	Molecular targeted treatments for fungal infections: the role of drug combinations. Trends in Molecular Medicine, 2003, 9, 269-276.	3.5	10
272	Pharmacogenetics and Proteomics of Anticancer Drugs in Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2003, 44, S115-S122.	0.6	10
273	In vitro studies on gemcitabine combinations with other antiproliferatives. Annals of Oncology, 2006, 17, v17-v19.	0.6	10
274	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, 1015-1021.	0.4	10
275	Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors. Expert Review of Anticancer Therapy, 2011, 11, 1303-1313.	1.1	10
276	Time-Dependent Pharmacokinetics of 5-Fluorouracil and Association With Treatment Tolerability in the Adjuvant Setting of Colorectal Cancer. Journal of Clinical Pharmacology, 2012, 52, 361-369.	1.0	10
277	Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation. British Journal of Pharmacology, 2013, 168, 266-275.	2.7	10
278	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer, 2015, 15, 874.	1.1	10
279	Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol. Cancer Chemotherapy and Pharmacology, 1990, 26, 403-408.	1.1	9
280	Suicide Gene Therapy With the Yeast Fusion Gene Cytosine Deaminase/Uracil Phosphoribosyltransferase Is Not Enough for Pancreatic Cancer. Pancreas, 2007, 35, 224-231.	0.5	9
281	Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. British Journal of Clinical Pharmacology, 2009, 67, 132-134.	1.1	9
282	Administration Interval and Daptomycin Toxicity: A Case Report of Rhabdomyolysis. Journal of Chemotherapy, 2010, 22, 434-435.	0.7	9
283	Promoting predictive, preventive and personalised medicine: European event of global importance. EPMA Journal, 2011, 2, 131-136.	3.3	9
284	Phase Ib of Sorafenib in Combination With Everolimus in Patients With Advanced Solid Tumors, Selected on the Basis of Molecular Targets. Oncologist, 2014, 19, 344-345.	1.9	9
285	Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015. Ecanermedscience, 2016, 10, 611.	0.6	9
286	Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule. Frontiers in Pharmacology, 2017, 8, 523.	1.6	9
287	CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone. Cancer Chemotherapy and Pharmacology, 2020, 86, 527-533.	1.1	9
288	Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. Journal of Clinical Oncology, 2004, 22, 2072-2072.	0.8	9

#	ARTICLE	IF	CITATIONS
289	Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4-aminohydroxydoxorubicin. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 29, 261-265.	1.1	8
290	Ultrastructural and Biochemical Evidence of Apoptosis Induced by a Novel Inhibitor of Protein Geranylgeranylation in Human MIA PaCa-2 Pancreatic Cancer Cells. <i>Ultrastructural Pathology</i> , 1998, 22, 253-261.	0.4	8
291	Acetylcholinesterase Blockade Does Not Account for the Adverse Cardiovascular Effects of the Antitumor Drug Irinotecan: A Preclinical Study. <i>Toxicology and Applied Pharmacology</i> , 2001, 177, 149-156.	1.3	8
292	Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications. <i>Epigenomics</i> , 2016, 8, 1151-1167.	1.0	8
293	Simultaneous, But Not Consecutive, Combination With Folate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo. <i>Oncology Research</i> , 2017, 25, 1129-1140.	0.6	8
294	Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 51-59.	2.0	8
295	Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring. <i>Neuro-Oncology</i> , 2019, 21, 1610-1611.	0.6	8
296	Serotonin syndrome and the T <sup>102</sup> C polymorphism of the 5-HT <sub>2A</sub> receptor: a case report. <i>Bipolar Disorders</i> , 2008, 10, 655-656.	1.1	7
297	Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. <i>Pharmacogenomics</i> , 2009, 10, 1225-1229.	0.6	7
298	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. <i>Annals of Oncology</i> , 2012, 23, 1370-1371.	0.6	7
299	Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 131, 208-213.	1.4	7
300	Should CYP2D6 be genotyped when treating with tamoxifen?. <i>Pharmacogenomics</i> , 2016, 17, 1967-1969.	0.6	7
301	Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment. <i>EPMA Journal</i> , 2017, 8, 69-73.	3.3	7
302	Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase. <i>Current Pharmaceutical Design</i> , 2017, 23, 2028-2034.	0.9	7
303	Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy. <i>Molecular Neurobiology</i> , 2018, 55, 1396-1404.	1.9	7
304	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102812.	2.0	7
305	Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment. <i>Pharmacogenomics</i> , 2019, 20, 1255-1257.	0.6	7
306	Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 154, 103066.	2.0	7

#	ARTICLE	IF	CITATIONS
307	Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103366.	2.0	7
308	Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 3738.	1.7	7
309	The effect of rhGM-CSF on the proliferation of osteogenic sarcoma cells. <i>American Journal of Hematology</i> , 1991, 37, 84-87.	2.0	6
310	Cholinergic toxic syndrome by the anticancer drug irinotecan: Acetylcholinesterase does not play a major role. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 263-271.	2.3	6
311	High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine+epirubicin+paclitaxel in metastatic breast cancer: a dose finding study. <i>Bone Marrow Transplantation</i> , 2003, 31, 275-280.	1.3	6
312	5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice. <i>Toxicology and Applied Pharmacology</i> , 2005, 203, 106-113.	1.3	6
313	Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1219-1227.	1.1	6
314	Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. <i>European Journal of Pharmacology</i> , 2003, 477, 17-21.	1.7	5
315	Stable analogues of geranylgeranyl diphosphate possessing improved geranylgeranyl versus farnesyl protein transferase inhibitory selectivity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 4405-4408.	1.0	5
316	Synthesis of Stable Analogues of Geranylgeranyl Diphosphate Possessing a (Z,E,E)-Geranylgeranyl Side Chain, Docking Analysis, and Biological Assays for Prenyl Protein Transferase Inhibition. <i>ChemMedChem</i> , 2006, 1, 218-224.	1.6	5
317	The Role of Pharmacogenetics in Adjuvant Treatment of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S27-S30.	0.5	5
318	Durable Complete Response to Frontline Docetaxel in an Advanced Prostate Cancer Patient with Favourable CYP1B1 Isoforms: Suggestion for Changing Paradigms?. <i>European Urology</i> , 2008, 54, 938-941.	0.9	5
319	Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. <i>Oncology</i> , 2016, 91, 283-288.	0.9	5
320	Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, e331-e333.	1.4	5
321	Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 87-96.	1.5	5
322	The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103602.	2.0	5
323	A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay. <i>Drugs Under Experimental and Clinical Research</i> , 1988, 14, 39-43.	0.3	5
324	Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. <i>Annals of Oncology</i> , 2018, 29, v102.	0.6	4

#	ARTICLE	IF	CITATIONS
325	Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position. <i>Annals of Oncology</i> , 2018, 29, 1893-1894.	0.6	4
326	Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study. <i>Cancers</i> , 2021, 13, 2445.	1.7	4
327	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 757-766.	1.5	4
328	Akt1 rs2498801 is related to survival in head and neck squamous cell cancer treated with radiotherapy. <i>Anticancer Research</i> , 2015, 35, 269-71.	0.5	4
329	Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. <i>Pharmacological Research</i> , 2022, 181, 106290.	3.1	4
330	Involvement of basic fibroblast growth factor in suramin-induced inhibition of V79/AP4 fibroblast cell proliferation. <i>British Journal of Cancer</i> , 1993, 67, 1209-1216.	2.9	3
331	Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity. <i>Il Farmaco</i> , 2003, 58, 85-89.	0.9	3
332	Steroids in Prostate Cancer: The Jury Is Still Out... and Even More Confused. <i>European Urology</i> , 2015, 67, 680-681.	0.9	3
333	Post-translational modifications and antioxidant properties of different therapeutic human serum albumins. <i>International Journal of Biological Macromolecules</i> , 2021, 183, 927-935.	3.6	3
334	Vascular Endothelial Growth Factor-A (VEGF-A) Single Nucleotide Polymorphisms and Endometriosis: Still a Controversial Issue. <i>Journal of Endometriosis</i> , 2009, 1, 94-101.	1.0	2
335	PP 92 Clinical and genetic characterization of dihydropyrimidine dehydrogenase deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele. <i>European Journal of Cancer</i> , 2011, 47, S16-S17.	1.3	2
336	Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1253-1267.	1.5	2
337	2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, S57.	0.5	2
338	Determination of Mitotane (DDD) and Principal Metabolite by a Simple HPLC-UV Method and Its Validation in Human Plasma Samples. <i>Separations</i> , 2021, 8, 63.	1.1	2
339	Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: a systematic review protocol. <i>BMJ Open</i> , 2021, 11, e048141.	0.8	2
340	TOP2A mRNA expression in HER2 negative breast cancer.. , 2009, , .		2
341	DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3532-3532.	0.8	2
342	Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival. <i>Clinical Lung Cancer</i> , 2022, 23, 510-521.	1.1	2

#	ARTICLE	IF	CITATIONS
343	Predicting Survival with Artificial Neural Networks. <i>Clinical Colorectal Cancer</i> , 2003, 2, 245.	1.0	1
344	Biologic Basis of Ovarian Metastasis of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2004, 3, 223-224.	1.0	1
345	Pharmacogenetics in oncology. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 74-78.	2.2	1
346	Pharmacogenetics in oncology. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 139.	2.2	1
347	Comment on "High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma". <i>Tumor Biology</i> , 2015, 36, 7397-7398.	0.8	1
348	AR-V7 detection in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer. <i>Annals of Oncology</i> , 2016, 27, vi248.	0.6	1
349	Should <i>CYP2D6</i> be genotyped when treating with tamoxifen?. <i>Pharmacogenomics</i> , 2017, 18, 755-756.	0.6	1
350	Pharmacogenetics and Personalized Medicine. , 2017, , 149-168.		1
351	Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. <i>Annals of Oncology</i> , 2017, 28, vi48.	0.6	1
352	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 254-255.	1.0	1
353	Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 760-774.	0.9	1
354	A pilot study of suramin in the treatment of metastatic renal cell carcinoma. , 1991, 67, 1509.		1
355	Results of a comprehensive pharmacogenetic analysis of dihydropyrimidine dehydrogenase in patients treated with fluoropyrimidines and patterns of polymorphisms partially related to treatment tolerability.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13057-e13057.	0.8	1
356	Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 382-382.	0.8	1
357	Variations of circulating KRAS amount as a biomarker to monitor chemotherapy response in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15794-e15794.	0.8	1
358	Correlation of expression of TK1 in plasma-derived exosomes with clinical response to CDK4/6 inhibitors in breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12037-12037.	0.8	1
359	Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management. <i>Pharmacogenomics</i> , 2022, 23, 119-134.	0.6	1
360	Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. <i>ESMO Open</i> , 2022, 7, 100381.	2.0	1

#	ARTICLE	IF	CITATIONS
361	Effect of suramin on ethanol-induced gastric mucosal injury: Relationship between tissue distribution and severity of damage. <i>Inflammopharmacology</i> , 1996, 4, 331-340.	1.9	0
362	Commentary on "The Role of Adjuvant Therapy After Liver Resection for Colorectal Metastases". <i>Clinical Colorectal Cancer</i> , 2001, 1, 167-168.	1.0	0
363	Synergistic chemotherapeutic activity of gemcitabine and fluvastatin on pancreas cancer in vitro. <i>Gastroenterology</i> , 2001, 120, A617.	0.6	0
364	Irinotecan in 5-Fluorouracil "Refractory Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2002, 2, 102-103.	1.0	0
365	Impact of Locoregional Approaches to Liver Metastases in Patients with Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2003, 3, 45-46.	1.0	0
366	Genetic Determinants in the Study of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2004, 4, 260-261.	1.0	0
367	Importance of Preclinical Investigations of the Integration of Capecitabine into Polychemotherapy Regimens. <i>Clinical Colorectal Cancer</i> , 2005, 4, 344.	1.0	0
368	610 POSTER Synergistic cytotoxicity, inhibition of Akt and c-Kit phosphorylation and modulation of gene expression by sorafenib and gemcitabine in human pancreatic cancer cells. <i>European Journal of Cancer, Supplement</i> , 2006, 4, 184.	2.2	0
369	D3-06: Correlation of cytidine deaminase and DNA repair genes polymorphisms with response and survival in gemcitabine/cisplatin treated advanced non-small-cell lung cancer patients. <i>Journal of Thoracic Oncology</i> , 2007, 2, S398-S399.	0.5	0
370	OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 9.	2.2	0
371	12 Pharmacogenetics of drug transporters. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 14.	2.2	0
372	Prognostic Value of CD133 Caused by Mutant K-Ras and B-Raf "Letter. <i>Clinical Cancer Research</i> , 2012, 18, 4473-4473.	3.2	0
373	Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 473-475.	1.5	0
374	P.2.d.040 Psychiatric patients carrying the CYP2C9*2 allele require lower doses of valproic acid to achieve target plasma levels. <i>European Neuropsychopharmacology</i> , 2013, 23, S387.	0.3	0
375	Embryonic stem cell pathways and chemotherapy response: an unexplored route. <i>Annals of Oncology</i> , 2013, 24, 558-559.	0.6	0
376	Breast Lymphomas Around Breast Implants. <i>Annals of Surgery</i> , 2014, 259, e4.	2.1	0
377	Lessons from the first e cancer symposium on angiogenesis in gastric cancer. <i>Ecancermedalscience</i> , 2015, 9, 553.	0.6	0
378	The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 109-130.	0.1	0

#	ARTICLE	IF	CITATIONS
379	Simultaneous, but not consecutive combination with folinate salts potentiates 5-fluorouracil antitumor activity in vitro. <i>European Journal of Cancer</i> , 2017, 72, S68.	1.3	0
380	Nicotine Metabolite Ratio in Smokers: A Real World Experience. <i>Clinical Therapeutics</i> , 2017, 39, e87.	1.1	0
381	PO-0630: The role of mc4r gene polymorphisms in gbm patients treated with concomitant radio-chemotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, S329-S330.	0.3	0
382	Dihydropyrimidine dehydrogenase (DPD) deficiency: how to translate it in clinical practice?. <i>Annals of Oncology</i> , 2017, 28, vi12-vi13.	0.6	0
383	Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer. <i>Annals of Oncology</i> , 2017, 28, vi47.	0.6	0
384	Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>Eur Urol</i> 2017;71:680-687. <i>European Urology</i> , 2018, 73, e11-e12.	0.9	0
385	Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: Independent actors or reciprocal drivers? A translational study by Meet-Uro group. <i>Annals of Oncology</i> , 2018, 29, viii27.	0.6	0
386	Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer. <i>Annals of Oncology</i> , 2018, 29, viii46.	0.6	0
387	Genome Wide Association Studies (GWAS)., 2018, , .		0
388	Selective induction of PD-L1 expression in plasma-derived exosomes by gemcitabine-nab-paclitaxel vs. FOLFIRINOX in pancreas cancer. <i>Annals of Oncology</i> , 2018, 29, viii53.	0.6	0
389	Analysis of the androgen receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients. <i>Annals of Oncology</i> , 2019, 30, v26.	0.6	0
390	Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: A study on circulating tumour DNA. <i>Annals of Oncology</i> , 2019, 30, v643.	0.6	0
391	Circulating biomarkers of response to immunotherapy in cancer treatment. <i>Pharmacogenomics</i> , 2019, 20, 1247-1249.	0.6	0
392	1932MO Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients. <i>Annals of Oncology</i> , 2020, 31, S1093.	0.6	0
393	Precision Medicine in Oncology: Glossary of Relevant Scientific Terms. UNIPA Springer Series, 2021, , 411-416.	0.1	0
394	Pharmacogenetics in Oncology. , 2006, , 129-153.		0
395	242: Pharmacogenetics Determinants of Anticancer Activity of Intravesical Gemcitabine in Patients with Superficial Transitional Cell Carcinoma (TCC) of The Bladder. <i>Journal of Urology</i> , 2007, 177, 81-81.	0.2	0
396	Induction of gemcitabine (GCB)-related genes by pemetrexed (MTA): Assessment of the best time interval between MTA and GCB administration. <i>Journal of Clinical Oncology</i> , 2007, 25, 14145-14145.	0.8	0

#	ARTICLE	IF	CITATIONS
397	Pharmacogenetics of Antiangiogenic Therapy. , 2008, , 477-486.		0
398	Pharmacogenetics of Angiogenesis. , 2010, , 233-242.		0
399	Abstract 4819: MicroRNA-21 (miR-21) in pancreatic ductal adenocarcinoma (PDAC): Correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity. , 2010, , .		0
400	Abstract 4375: Sunitinib alone and in combination with SN-38 is active against anaplastic thyroid cancer. , 2012, , .		0
401	Abstract P5-17-06: The deficient eNOS c.894G>T genotype is not associated with increased severity of hypertension and proteinuria in breast cancer patients receiving bevacizumab. , 2012, , .		0
402	Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR.. Journal of Clinical Oncology, 2013, 31, e22056-e22056.	0.8	0
403	Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens.. Journal of Clinical Oncology, 2013, 31, 11058-11058.	0.8	0
404	Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial.. Journal of Clinical Oncology, 2013, 31, 3603-3603.	0.8	0
405	Abstract P1-08-31: Putative role of genetic variants of eNOS in survival and toxicity of patients given antiangiogenic therapy. , 2013, , .		0
406	Effect of Suramin on Ethanol-Induced Gastric Mucosal Injury: Relationship between Tissue Distribution and Severity of Damage. , 1997, , 129-138.		0
407	Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.. Journal of Clinical Oncology, 2014, 32, 11056-11056.	0.8	0
408	Association of eNOS polymorphisms with clinical outcome in bevacizumab-treated breast cancer patients.. Journal of Clinical Oncology, 2014, 32, e22075-e22075.	0.8	0
409	Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia. Blood, 2015, 126, 4838-4838.	0.6	0
410	KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA.. Journal of Clinical Oncology, 2016, 34, e20526-e20526.	0.8	0
411	The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience. Blood, 2016, 128, 3951-3951.	0.6	0
412	Characteristics of smokers according to their Nicotine Metabolite Ratio, preliminary results from a real-life experience. , 2017, , .		0
413	Listening understanding and acting (lung): focus on communicational issue in thoracic oncology. Translational Cancer Research, 2018, 8, S16-S22.	0.4	0
414	Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World. Clinical Cancer Drugs, 2018, 4, .	0.3	0



#	ARTICLE	IF	CITATIONS
415	Association of PD-L1 mRNA levels in plasma-derived exosomes with response to nivolumab and pembrolizumab in melanoma and NSCLC.. Journal of Clinical Oncology, 2018, 36, 210-210.	0.8	0
416	Selective induction of PD-L1 expression in plasma-derived exosomes by gem-nab-paclitaxel vs. folfirinox in pancreas cancer.. Journal of Clinical Oncology, 2018, 36, e24128-e24128.	0.8	0
417	PLASMA/SALIVA AND GENOTYPIC/PHENOTYPIC DIFFERENCES OF NICOTINE METABOLITE RATIO.. , 2018, , .		0
418	Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.. Journal of Clinical Oncology, 2019, 37, e14054-e14054.	0.8	0
419	A real-world application of liquid biopsy (LB) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2020, 38, 48-48.	0.8	0
420	Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region. Farmeconomia E Percorsi Terapeutici, 2020, 21, .	0.2	0
421	Plasma pharmacokinetics of cinmetacin following oral administration in healthy volunteers. Arzneimittelforschung, 1988, 38, 129-31.	0.5	0
422	Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. Journal of Clinical Oncology, 2004, 22, 2072-2072.	0.8	0